Health Technology Policies

The Bureau of Industry and Security has named nine product classes and 19 jurisdictions that can ship specialty medicines into the United States at a zero tariff, while the 100 percent Section 232 duty reaches most patented pharmaceuticals on 29 September 2026. Companies arguing an urgent U.S. health need now have a defined route to apply. #SyenzaNews #MarketAccess #PharmaceuticalTariffs

A National Press Foundation briefing on drug prices and workforce shortages: separate list price from net price, ask which goal a policy serves, and check whether more clinicians really mean more appointments. #SyenzaNews #HealthEconomics #MarketAccess

Nine pharma chairs, from AstraZeneca to Sanofi, warn Europe is losing the pharmaceutical investment race to the US and China, and call on governments to treat medicines as strategic infrastructure. #SyenzaNews #pharmaceuticals #MarketAccess #drugdevelopment

Alec Morton of NUS explains how AI is changing health technology assessment, what stays human, and why cheaper analysis could mean more health economics.

The European Commission's EU Public Procurement Act would make quality, not price, the default for public tenders. EFPIA supports the shift, with one warning: resilience should not become local-content rules. #SyenzaNews #EUProcurement #Medicines #MarketAccess #HealthPolicy

Aspen Pharmacare has walked away from local lenacapavir manufacturing over the lack of guaranteed volumes, and is instead backing Merck's once-monthly oral PrEP pill, alimatravir. #SyenzaNews #HIV #PrEP #MarketAccess

Insurers are spending billions on breakthrough medicines, but the tests that decide who gets them are still an afterthought. Kathryn Phillips lays out four reforms to link drug and diagnostic policy pathways. #SyenzaNews #diagnostics #healtheconomics #MarketAccess

The European Medicines Agency’s Management Board met in Amsterdam on 10 and 11 June 2026. The European Commission reported that the first EU joint clinical assessment report appeared on 9 June 2026. Since the Health Technology Assessment Regulation took effect in January 2025, 18 JCAs have started. Seven Joint Scientific Consultations have finished under the Regulation, and the first JCAs for medical devices and in vitro diagnostics will begin in June 2026. Initiative Status Timing First EU joint clinical assessment […]

How are cell therapies redefining cancer care through rigorous HTA evaluation? INCA’s latest analysis highlights how CAR-T and other advanced cell therapies are shifting oncology paradigms—balancing innovation with evidence-based access and cost-effectiveness. Explore the full breakdown and its implications for global cancer treatment. #SyenzaNews #oncology #precisionmedicine #innovation #MarketAccess

Is the US childhood vaccine schedule really out of step with peer nations? A new analysis finds it aligns closely with other developed countries in both the number and timing of recommended vaccines. Explore the full comparison and what it means for vaccine policy. #SyenzaNews #globalhealth #HealthcareInnovation #healthcarepolicy #innovation

Is the PRIME scheme growing more exclusive for innovative medicines? Eligibility criteria for the European Medicines Agency’s PRIME scheme remain highly selective in 2026, underscoring the rigorous standards required to secure early regulatory support for therapies addressing unmet medical needs. Discover what this means for drug developers and patients. #SyenzaNews #regulatoryaffairs #drugdevelopment #innovation #MarketAccess

How is NICE expanding treatment options for HFpEF patients? The UK’s National Institute for Health and Care Excellence has approved finerenone, giving clinicians a new evidence-based therapy to improve outcomes in heart failure with preserved ejection fraction. This milestone broadens the therapeutic landscape and reinforces the value of targeted drug development. Read the full analysis. #SyenzaNews #pharmaceuticals #HealthcareInnovation #innovation #MarketAccess